Tenax Therapeutics (TENX) Reiterated at Overweight by Cantor Fitzgerald: Ph3 Data in Q3

June 24, 2026 6:50 AM

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $35.00 price target on Tenax Therapeutics (NASDAQ: TENX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found